Home > Annual Financials > MARKSANS PHARMA

MARKSANS PHARMA Financial Statement Analysis
[BOM: 524404|NSE : MARKSANS]

The Revenues of MARKSANS PHARMA have increased by 17.56% YoY .
The Earnings Per Share (EPS) of MARKSANS PHARMA has increased by 17.69 % YoY.
REVENUES
OPERATING MARGIN
PROFIT AFTER TAX
EPS
ROCE

MARKSANS PHARMA Last 5 Annual Financial Results
[BOM: 524404|NSE : MARKSANS]

ConsolidatedMar2024
Mar2023
Mar2022
Mar2021
Mar2020
Revenues ₹2,177 Cr₹1,852 Cr₹1,491 Cr₹1,376 Cr₹1,134 Cr
Expenses ₹1,719 Cr₹1,513 Cr₹1,232 Cr₹1,037 Cr₹942 Cr
Operating Profit (Excl OI) ₹459 Cr₹339 Cr₹259 Cr₹340 Cr₹192 Cr
Other Income ₹50 Cr₹59 Cr₹42 Cr₹6.69 Cr₹0.33 Cr
Interest ₹11 Cr₹9.13 Cr₹8.45 Cr₹7.99 Cr₹8.75 Cr
Depreciation ₹74 Cr₹52 Cr₹45 Cr₹36 Cr₹27 Cr
Profit Before Tax ₹424 Cr₹338 Cr₹248 Cr₹302 Cr₹157 Cr
Profit After Tax ₹315 Cr₹265 Cr₹187 Cr₹239 Cr₹121 Cr
Consolidated Net Profit ₹314 Cr₹266 Cr₹185 Cr₹236 Cr₹117 Cr
Earnings Per Share (Rs)₹6.92₹5.88₹4.51₹5.76₹2.86
PAT Margin (%)13.7513.0112.0617.1410.65
ROE(%)16.5318.5918.7231.3320.49
ROCE(%)22.4022.8923.8239.7625.57
Total Debt/Equity(x)0.010.020.040.020.03

Key Financials

Market Cap : ₹ 11,459.2 Cr
Revenue (TTM) : ₹ 2,378.7 Cr
Net Profit(TTM) : ₹ 347.4 Cr
EPS (TTM) : ₹ 7.7
P/E (TTM) : 33.0

Industry Peers & Returns1W1M1Y
MARKSANS PHARMA -4.5% -12.9% 62.5%
SUN PHARMACEUTICAL INDUSTRIES 2.6% -1.1% 38.3%
CIPLA -2.4% -5.2% 10.6%
DR REDDYS LABORATORIES -5.9% -9.6% 14.5%
ZYDUS LIFESCIENCES -3.9% -0.3% 40.6%
DIVIS LABORATORIES -3.8% -1.9% 60.1%
MANKIND PHARMA -7.4% -14% 21.4%
TORRENT PHARMACEUTICALS 2.6% -5% 29%
LUPIN 0.1% -2.2% 52.5%


MARKSANS PHARMA Revenues
[BOM: 524404|NSE : MARKSANS]

Y-o-Y

17.56 %

5 Yr CAGR

17.71 %

Years Revenues % Change
Mar2024 ₹2,177 Cr
17.56
Mar2023 ₹1,852 Cr
24.23
Mar2022 ₹1,491 Cr
8.33
Mar2021 ₹1,376 Cr
21.33
Mar2020 ₹1,134 Cr -


MARKSANS PHARMA Operating Profit
[BOM: 524404|NSE : MARKSANS]

Y-o-Y

35.15 %

5 Yr CAGR

24.28 %

Years Operating Profit % Change
Mar2024 ₹459 Cr
35.15
Mar2023 ₹339 Cr
31.07
Mar2022 ₹259 Cr
-23.77
Mar2021 ₹340 Cr
76.65
Mar2020 ₹192 Cr -

Operating Margins
Y-o-Y

14.96 %

5 Yr CAGR

5.58 %

Years Operating Margin% % Change
Mar2024 21.06%
14.96
Mar2023 18.32%
5.53
Mar2022 17.36%
-29.66
Mar2021 24.68%
45.60
Mar2020 16.95% -

MARKSANS PHARMA Profit After Tax
[BOM: 524404|NSE : MARKSANS]

Y-o-Y

17.80 %

5 Yr CAGR

27.96 %

Years Profit After Tax % Change
Mar2024 ₹314 Cr
17.80
Mar2023 ₹266 Cr
44.29
Mar2022 ₹185 Cr
-21.77
Mar2021 ₹236 Cr
101.62
Mar2020 ₹117 Cr -

PAT Margins
Y-o-Y

5.69 %

5 Yr CAGR

6.60 %

Years PAT Margin(%) % Change
Mar2024 13.75 %
5.69
Mar2023 13.01 %
7.88
Mar2022 12.06 %
-29.64
Mar2021 17.14 %
60.94
Mar2020 10.65 % -

MARKSANS PHARMA Earnings Per Share (EPS)
[BOM: 524404|NSE : MARKSANS]

Y-o-Y

17.69 %

5 Yr CAGR

24.72 %

Years EPS % Change
Mar2024 ₹6.92
17.69
Mar2023 ₹5.88
30.38
Mar2022 ₹4.51
-21.70
Mar2021 ₹5.76
101.40
Mar2020 ₹2.86 -

MARKSANS PHARMA Return on Capital Employed (ROCE)
[BOM: 524404|NSE : MARKSANS]

Y-o-Y

-2.14 %

5 Yr CAGR

-3.25 %

Years ROCE % Change
Mar2024 22.4%
-2.14
Mar2023 22.89%
-3.90
Mar2022 23.82%
-40.09
Mar2021 39.76%
55.49
Mar2020 25.57% -

MARKSANS PHARMA Share Price vs Sensex

Current Share Price : ₹252.9
Current MarketCap: ₹ 11,459.2 Cr
Updated EOD on :Jan 24,2025

Share Price Returns(%) 1 Week 1 Month 1 Year
MARKSANS PHARMA

-4.5%

-12.9%

62.5%

SENSEX

-0.6%

-2.9%

6.3%

MARKSANS PHARMA related INDICES

BSE Indices1W1M1Y
S&P BSE ALLCAP -0.3% -3.5% 35.8%
S&P BSE HEALTHCARE -1.1% -4.3% 28.7%
S&P BSE MIDSMALLCAP -3.4% -8.4% 12.3%
S&P BSE SMALL CAP -4.2% -8.9% 12.8%
No NSE index found

You may also like the below Video Courses


FAQ about MARKSANS PHARMA Financials


How the annual revenues of MARKSANS PHARMA have changed ?

The Revenues of MARKSANS PHARMA have increased by 17.56% YoY .

How the Earnings per Share (EPS) of MARKSANS PHARMA have changed?

The Earnings Per Share (EPS) of MARKSANS PHARMA has increased by 17.69 % YoY .